Nuveen LLC Purchases Shares of 673,343 MoonLake Immunotherapeutics $MLTX

Nuveen LLC acquired a new stake in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 673,343 shares of the company's stock, valued at approximately $26,308,000. Nuveen LLC owned approximately 1.05% of MoonLake Immunotherapeutics at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Westfield Capital Management Co. LP raised its holdings in shares of MoonLake Immunotherapeutics by 9.4% in the first quarter. Westfield Capital Management Co. LP now owns 1,434,770 shares of the company's stock valued at $56,056,000 after acquiring an additional 123,151 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of MoonLake Immunotherapeutics by 8.2% in the first quarter. PNC Financial Services Group Inc. now owns 9,200 shares of the company's stock valued at $359,000 after acquiring an additional 700 shares in the last quarter. Jefferies Financial Group Inc. raised its holdings in shares of MoonLake Immunotherapeutics by 60.0% in the first quarter. Jefferies Financial Group Inc. now owns 10,000 shares of the company's stock valued at $391,000 after acquiring an additional 3,750 shares in the last quarter. US Bancorp DE raised its holdings in shares of MoonLake Immunotherapeutics by 114.4% in the first quarter. US Bancorp DE now owns 2,208 shares of the company's stock valued at $86,000 after acquiring an additional 1,178 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in shares of MoonLake Immunotherapeutics in the first quarter valued at about $332,000. 93.85% of the stock is currently owned by institutional investors.

MoonLake Immunotherapeutics Stock Up 3.1%

Shares of MoonLake Immunotherapeutics stock traded up $1.6950 during trading on Friday, reaching $55.8650. The company's stock had a trading volume of 50,130 shares, compared to its average volume of 473,342. MoonLake Immunotherapeutics has a 1-year low of $31.42 and a 1-year high of $58.26. The company has a quick ratio of 16.65, a current ratio of 16.65 and a debt-to-equity ratio of 0.21. The company has a market cap of $3.59 billion, a price-to-earnings ratio of -20.07 and a beta of 1.27. The company has a 50-day simple moving average of $50.28 and a two-hundred day simple moving average of $43.68.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.14). During the same quarter in the previous year, the business posted ($0.39) EPS. As a group, equities analysts forecast that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current year.

Wall Street Analysts Forecast Growth

MLTX has been the subject of several recent research reports. The Goldman Sachs Group lifted their price objective on MoonLake Immunotherapeutics from $74.00 to $82.00 and gave the company a "buy" rating in a report on Wednesday, August 6th. Wolfe Research upgraded shares of MoonLake Immunotherapeutics from a "peer perform" rating to an "outperform" rating and set a $61.00 target price for the company in a report on Monday, May 19th. Needham & Company LLC reiterated a "buy" rating and issued a $66.00 target price on shares of MoonLake Immunotherapeutics in a report on Tuesday, May 13th. Redburn Atlantic upgraded shares of MoonLake Immunotherapeutics to a "hold" rating in a report on Monday, July 28th. Finally, Royal Bank Of Canada reiterated an "outperform" rating and issued a $67.00 target price on shares of MoonLake Immunotherapeutics in a report on Tuesday, June 3rd. Seven analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, MoonLake Immunotherapeutics currently has an average rating of "Moderate Buy" and an average price target of $74.43.

MoonLake Immunotherapeutics Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.